{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:44:23Z","timestamp":1767703463332},"reference-count":44,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2008,7,14]],"date-time":"2008-07-14T00:00:00Z","timestamp":1215993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:p><jats:bold>Background:\u2002<\/jats:bold> Pharmacological interventions to treat depressive symptoms associated with Parkinson\u2019s disease (PD) are limited. Whether selective serotonine re\u2010uptake inhibitors increase parkinsonism or have clinically significant interactions with antiparkinsonian drugs is unresolved.<\/jats:p><jats:p><jats:bold>Purpose:\u2002<\/jats:bold> We used a naturalistic approach to prospectively investigate the long\u2010term effects on motor status of adding sertraline in a large sample of community\u2010dwelling PD patients with depressive symptoms.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Main outcome measure was the motor part of the Unified PD Rating Scale (UPDRS) at baseline and at 1\u2010, 3\u2010, and 6\u2010month follow\u2010up. Secondary measures were the change in antiparkinsonian drugs expressed as total levodopa equivalent dose and the scores of the Hospital Anxiety and Depression Scale (HADS). Of the 374 patients included, 310 (82%) completed the study.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Treatment with sertraline (mean dose 66.0\u2003\u00b1\u200329.8\u2003mg) resulted in improvement in all UPDRS domains along with a significant decrease of the HADS scores. A modest but significant increase of the total dose of levodopa, without significant change of total levodopa equivalent dose, was observed. Almost 8% of patients discontinued medication for adverse events, mainly related to the gastrointestinal system.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Although worsening of tremor was observed in some patients, active management of depression with sertraline appears to have a positive impact on parkinsonism.<\/jats:p>","DOI":"10.1111\/j.1468-1331.2008.02218.x","type":"journal-article","created":{"date-parts":[[2008,7,14]],"date-time":"2008-07-14T11:12:18Z","timestamp":1216033938000},"page":"953-959","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Motor changes during sertraline treatment in depressed patients with Parkinson\u2019s disease*"],"prefix":"10.1111","volume":"15","author":[{"given":"J.","family":"Kulisevsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Pagonabarraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Pascual\u2010Sedano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gironell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Garc\u00eda\u2010S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mart\u00ednez\u2010Corral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,8,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.69.3.308"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2007.06.011"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2004.52219.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10114"},{"key":"e_1_2_6_6_2","article-title":"Therapies for depression in Parkinson\u2019s disease","volume":"3","author":"Shabnam GN","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"e_1_2_6_7_2","first-page":"S112","article-title":"Management of Parkinson\u2019s disease: an evidence\u2010based review. Treatment of depression in idiopathic Parkinson\u2019s disease","volume":"17","author":"Lang AE","year":"2002","journal-title":"Movement Disorders"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1996.00550020087019"},{"issue":"2","key":"e_1_2_6_9_2","first-page":"A124","article-title":"A multicentric cross\u2010sectional survey of the prevalence and correlates of neuropsychiatric symptoms in a population of Parkinson\u2019s disease without dementia","volume":"66","author":"Kulisevsky J","year":"2006","journal-title":"Neurology"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.30.12.1326"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh445"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.5.642"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-004-0956-9"},{"issue":"4","key":"e_1_2_6_14_2","first-page":"S1","article-title":"Management of Parkinson\u2019s disease: an evidence\u2010based review","volume":"17","author":"Movement Disorders Society","year":"2002","journal-title":"Movement Disorders"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000215428.46057.3d"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01548.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1980.tb03028.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n1104"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20895"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.4.1168"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006223422507"},{"key":"e_1_2_6_22_2","article-title":"Assessing observational studies of medical treatments","volume":"2","author":"Hartz A","year":"2005","journal-title":"Emergent Themes in Epidemiology"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006223422506"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2007.00818.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200118050-00006"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199957040-00005"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.8.1497"},{"key":"e_1_2_6_28_2","first-page":"813","article-title":"The international classification of WHO diseases (ICD\u201010) and its application in neurology (ICD\u201010 NA)","volume":"150","author":"Orgogozo JM","year":"1994","journal-title":"Revue Neurologique (Paris)"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21333"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0738-3991(95)00757-Q"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.17.5.427"},{"key":"e_1_2_6_33_2","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20210"},{"key":"e_1_2_6_35_2","article-title":"Sertraline for the treatment of depression in Parkinson\u2019s disease","volume":"13","author":"Meara J","year":"1998","journal-title":"Movement Disorders"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120522"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-006-0067-5"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.865"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2001.01491.x"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.3.710"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1060937"},{"key":"e_1_2_6_42_2","first-page":"311","article-title":"Sertraline: a new antidepressant","volume":"48","author":"Auster R","year":"1993","journal-title":"American Family Physician"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200211000-00008"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20397"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2006.05.024"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1331.2008.02218.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1331.2008.02218.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:40:41Z","timestamp":1696898441000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1331.2008.02218.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,11]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1111\/j.1468-1331.2008.02218.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02218.x","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,11]]},"assertion":[{"value":"2008-08-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}